DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1914)

Ulcerative Colitis | Emerging Therapies | Xeljanz (Ulcerative Colitis) Launch Tracking Wave 2

Ulcerative Colitis | Emerging Therapies | Xeljanz (Ulcerative Colitis) Launch Tracking Wave 2

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for moderate to severe UC. Not only does Xeljanz provide a novel mechanism of action for the treatment of UC, but, as an oral therapy, it also has a notable delivery advantage compared with the biologics and will help fulfill a key unmet need. However, tumor necrosis factor-alpha (TNF-ɑ) inhibitors’ entrenched position could pose a formidable barrier to Xeljanz’s uptake; indeed, its positioning in the treatment algorithm is yet to be determined. The Ulcerative Colitis Emerging Therapy series tracks the awareness, trial, and use of Xeljanz for UC since its approval in late May 2018. In addition, the series examines physician-anticipated trends in UC treatment, particularly in terms of Xeljanz’s uptake, and Pfizer’s promotional efforts.

QUESTIONS ANSWERED

  • What is the awareness of, familiarity with, and perceptions related to Xeljanz among U.S. gastroenterologists?
  • Among prescribers, to which patients are they prescribing Xeljanz, what are the reasons for prescribing the agent, and how satisfied are they with Xeljanz ?
  • How do prescribers and nonprescribers compare across key metrics?
  • How are the trial and adoption of Xeljanz compared with that of other recent product launches in the autoimmune market?

CONTENT HIGHLIGHTS

  • Geography: United States
  • Primary research: Survey of approximately 75 U.S. gastroenterologists for each wave
  • Key metrics included: Unaided and aided awareness of Xeljanz; familiarity with and impressions of Xeljanz; prescriber and nonprescriber profiles; willingness to prescribe Xeljanz; performance of Xeljanz on key attributes; sales representative frequency, reach, and satisfaction; benchmarking against previously launched UC agents

PRODUCT DESCRIPTION: Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.

Table of contents

  • Xeljanz (Ulcerative Colitis) Launch Tracking Wave 2
    • Ulcerative Colitis Emerging Therapies Xeljanz US Wave 2 (February 2019)

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Qinghui Yu, PhD
  • Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.

Purchase Report

Recent reports:
You may also be interested in: